Chemotherapy in Cancer Patients with Comorbidity.
10.5230/jkgca.2004.4.2.59
- Author:
Hei Cheul JEUNG
1
;
Yong Wha MOON
Author Information
1. Cancer Metastasis Research Center, Yonsei Cancer Center, Seoul, Korea. jeunghc1123@yumc.yonsei.ac.kr
- Publication Type:Review
- Keywords:
Comorbidity;
Chemotherapy
- MeSH:
Comorbidity*;
Drug Therapy*;
Humans;
Liver Diseases;
Mortality;
Pharmacokinetics;
Quality of Life;
Stomach Neoplasms
- From:Journal of the Korean Gastric Cancer Association
2004;4(2):59-74
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This report attempts to explain the (i) implications of comorbidity for research and practice in the fieldo of oncology, (ii) the approach for dosing of anti-cancer drugs in the presence of comorbidity, as an example of its clinical application, and finally (iii) the dosing guidelines for the anticancer drugs clinically active in gastric cancer in the presence of renal or liver dysfunction. This has resulted from the idea of approaching comorbidity in a systematic way and of integrating it with oncologic decisions. Various methods have been used to assess comorbidity. However, significant work remains to be done to analyze how various diseases combine to influence the oncologic outcome. The main end-point explored so far has been mortality, but a largely open challenge remains to correlate comorbidity with treatment tolerance and functional and quality of life, as well as to integrate it in clinical decision-making. Cancer chemotherapy in comorbidity should be considered as an example of the need for dose optimization in individual patients, and it should be determined by considering the basic principles of the pharmacokinetics and the pharmacodynamics of the agents. This review analyzes the available data on the pharmacokinetics and the toxicities of anti-cancer agents in the comorbidity population.
